BG105651A - Антагонист на витронектиновия рецептор - Google Patents

Антагонист на витронектиновия рецептор

Info

Publication number
BG105651A
BG105651A BG105651A BG10565101A BG105651A BG 105651 A BG105651 A BG 105651A BG 105651 A BG105651 A BG 105651A BG 10565101 A BG10565101 A BG 10565101A BG 105651 A BG105651 A BG 105651A
Authority
BG
Bulgaria
Prior art keywords
receptor antagonist
vitronectin receptor
vitronectin
osteoporosis
useful
Prior art date
Application number
BG105651A
Other languages
English (en)
Other versions
BG65118B1 (bg
Inventor
William Miller
Peter Manley
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of BG105651A publication Critical patent/BG105651A/bg
Publication of BG65118B1 publication Critical patent/BG65118B1/bg

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Съединението има формула@@То е витронектинов рецепторен антагонист и е приложимо при лечението на остеопороза. Изобретението се отнася и до фармацевтично приемлива сол на посоченото съединение.
BG105651A 1998-12-04 2001-06-26 Антагонист на витронектиновия рецептор BG65118B1 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11090398P 1998-12-04 1998-12-04

Publications (2)

Publication Number Publication Date
BG105651A true BG105651A (bg) 2002-02-28
BG65118B1 BG65118B1 (bg) 2007-03-30

Family

ID=22335565

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105651A BG65118B1 (bg) 1998-12-04 2001-06-26 Антагонист на витронектиновия рецептор

Country Status (39)

Country Link
US (1) US6495560B1 (bg)
EP (1) EP1146874B1 (bg)
JP (1) JP4481504B2 (bg)
KR (1) KR100620485B1 (bg)
CN (1) CN1147300C (bg)
AP (1) AP1534A (bg)
AR (1) AR035006A1 (bg)
AT (1) ATE277043T1 (bg)
AU (1) AU754408B2 (bg)
BG (1) BG65118B1 (bg)
BR (1) BR9915879A (bg)
CA (1) CA2353415A1 (bg)
CO (1) CO5150166A1 (bg)
CZ (1) CZ20011963A3 (bg)
DE (1) DE69920518T2 (bg)
DK (1) DK1146874T3 (bg)
DZ (1) DZ2954A1 (bg)
EA (1) EA003254B1 (bg)
EG (1) EG24025A (bg)
ES (1) ES2229798T3 (bg)
HK (1) HK1042037B (bg)
HU (1) HUP0104804A3 (bg)
ID (1) ID28811A (bg)
IL (2) IL143390A0 (bg)
MA (1) MA25265A1 (bg)
NO (1) NO318895B1 (bg)
NZ (1) NZ511876A (bg)
OA (1) OA11724A (bg)
PE (1) PE20001563A1 (bg)
PL (1) PL195973B1 (bg)
PT (1) PT1146874E (bg)
SI (1) SI1146874T1 (bg)
SK (1) SK7452001A3 (bg)
TR (1) TR200101654T2 (bg)
TW (1) TW482673B (bg)
UA (1) UA71586C2 (bg)
UY (1) UY25824A1 (bg)
WO (1) WO2000033838A1 (bg)
ZA (1) ZA200104398B (bg)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001269821A1 (en) 2000-06-15 2001-12-24 Barbara Chen Cycloalkyl alkanoic acids as integrin receptor antagonists
US6943156B2 (en) * 2000-10-24 2005-09-13 Merck & Co., Inc Dibenzoxazepine αv integrin receptor antagonist
CA2436130A1 (en) 2001-01-29 2002-08-08 3-Dimensional Pharmaceuticals, Inc. Substituted indoles and their use as integrin antagonists
US6872730B2 (en) * 2001-04-27 2005-03-29 3-Dimensional Pharmaceuticals, Inc. Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
CA2510084A1 (en) 2002-12-20 2004-07-15 Pharmacia Corporation Thiazole compounds as integrin receptor antagonists derivatives
GB0319069D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Therapeutically useful compounds
WO2006069079A2 (en) * 2004-12-21 2006-06-29 Smithkline Beecham Corporation Methods and formulations
EA022046B1 (ru) 2010-07-14 2015-10-30 Новартис Аг Гетероциклические соединения, агонисты рецептора ip
TW201335160A (zh) 2012-01-13 2013-09-01 Novartis Ag Ip受體激動劑之雜環化合物
ES2637719T3 (es) 2013-02-13 2017-10-16 Novartis Ag Compuestos heterocíclicos agonistas del receptor IP
EP4249471A3 (en) 2013-09-24 2023-10-18 FUJIFILM Corporation Pharmaceutical composition of a nitrogen-containing compound or salt thereof, or metal complex thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2687154B1 (fr) 1992-02-07 1995-05-12 Rhone Poulenc Rorer Sa Nouveau derive de l'isoindolinone, sa preparation et les compositions pharmaceutiques qui le contiennent.
SI0910563T1 (en) * 1995-06-29 2003-10-31 Smithkline Beecham Corporation Integrin receptor antagonists
WO1998013278A1 (de) * 1996-09-27 1998-04-02 Merkler, H. Tank für flüssigkeiten, insbesondere für chemisch aggressive flüssigkeiten
EP0946180A4 (en) 1996-10-07 2003-07-23 Smithkline Beecham Corp METHODS FOR STIMULATING BONE FORMATION
UY24949A1 (es) 1997-04-08 2001-04-30 Smithkline Beecham Corp Compuestos calcilíticos

Also Published As

Publication number Publication date
AP1534A (en) 2006-01-09
PT1146874E (pt) 2005-02-28
ID28811A (id) 2001-07-05
KR100620485B1 (ko) 2006-09-13
BR9915879A (pt) 2002-02-13
ATE277043T1 (de) 2004-10-15
KR20010080669A (ko) 2001-08-22
BG65118B1 (bg) 2007-03-30
AR035006A1 (es) 2004-04-14
AU1750200A (en) 2000-06-26
EA200100618A1 (ru) 2001-12-24
CN1147300C (zh) 2004-04-28
NO20012732L (no) 2001-08-01
EG24025A (en) 2008-03-26
NZ511876A (en) 2004-02-27
SK7452001A3 (en) 2001-12-03
ES2229798T3 (es) 2005-04-16
DE69920518D1 (de) 2004-10-28
CA2353415A1 (en) 2000-06-15
HUP0104804A2 (hu) 2002-05-29
NO20012732D0 (no) 2001-06-01
DK1146874T3 (da) 2005-01-31
JP4481504B2 (ja) 2010-06-16
DE69920518T2 (de) 2005-09-22
SI1146874T1 (en) 2005-04-30
EP1146874A1 (en) 2001-10-24
MA25265A1 (fr) 2001-10-01
HUP0104804A3 (en) 2002-12-28
NO318895B1 (no) 2005-05-18
UA71586C2 (en) 2004-12-15
JP2003523931A (ja) 2003-08-12
PE20001563A1 (es) 2001-02-09
EP1146874B1 (en) 2004-09-22
TW482673B (en) 2002-04-11
EA003254B1 (ru) 2003-02-27
DZ2954A1 (fr) 2004-06-20
HK1042037B (zh) 2005-07-29
ZA200104398B (en) 2002-05-29
CO5150166A1 (es) 2002-04-29
IL143390A (en) 2006-07-05
AU754408B2 (en) 2002-11-14
PL195973B1 (pl) 2007-11-30
OA11724A (en) 2005-01-26
TR200101654T2 (tr) 2002-03-21
CN1334730A (zh) 2002-02-06
PL348702A1 (en) 2002-06-03
EP1146874A4 (en) 2002-06-05
IL143390A0 (en) 2002-04-21
UY25824A1 (es) 2001-07-31
US6495560B1 (en) 2002-12-17
WO2000033838A1 (en) 2000-06-15
HK1042037A1 (en) 2002-08-02
CZ20011963A3 (cs) 2001-11-14

Similar Documents

Publication Publication Date Title
BG106586A (bg) Пиразолопиримидини като терапевтични средства
MX9805253A (es) Antagonistas del receptor de vitronectina.
IL152770A0 (en) Gabapentin analogues for sleep disorders
AU4086101A (en) Sulphonamido-substituted bridged bicycloalkyl derivatives
IL149592A0 (en) Synthesis of 2'-deoxy-l-nucleosides
MX9700041A (es) Antagonistas de receptor de vitronectina.
MX9605915A (es) Derivados de piperazina como antagonistas de 5ht1a.
TR200000786T2 (tr) Vitronektin reseptör antagonisti
BR9813208A (pt) Antagonista receptor de vitronectina
BG105651A (bg) Антагонист на витронектиновия рецептор
BG104740A (bg) Мета - азациклични аминобензоени киселини и технипроизводни, ефикасни като антагонисти на интегрина
BG104314A (bg) Антагонисти на витронектинов рецептор
PL346981A1 (en) 2-methyl-thieno-benzodiazepine formulation
BG102589A (bg) 3-азетидинилалкилпиперидини или - пиролидини катотахикининови антагонисти
MX9800483A (es) Derivados de piperazina y su uso como antagonistas de 5-ht1a.
NZ515025A (en) Solvates of pymetrozine
BG104038A (bg) Използване на специфичен антагонист на рецептора 5нт2 за получаване на лекарствени средства за лечение на апнея по време на сън
IL134263A0 (en) Use of phanquinone for the treatment of alzheimer's disease
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
WO2001017959A3 (en) Vitronectin receptor antagonists
WO2000007544A3 (en) Vitronectin receptor antagonists
BG106151A (bg) Фармацевтичен комплекс
UA29461C2 (uk) Засіб для лікування амілоїдозу, спосіб лікування амілоїдозу
HUP0201610A2 (en) Derivatives of 4'-demycarosyl-8a-aza-8a-homotylosin
PL341487A1 (en) Plater's wedge